AT-1501 Emerging Drug Insight and Market Forecast – 2032

AT-1501 Emerging Drug Insight and Market Forecast – 2032

“AT-1501 Emerging Drug Insight and Market Forecast – 2032” report provides comprehensive insights about AT-1501 for Amyotrophic Lateral Sclerosis in seven major markets. A detailed picture of the AT-1501 for Amyotrophic Lateral Sclerosis in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the AT-1501 for Amyotrophic Lateral Sclerosis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AT-1501 market forecast analysis for Amyotrophic Lateral Sclerosis in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

AT-1501 is a humanized IgG1 anti-CD40L antibody with a high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half-life. Importantly, AT-1501 targets CD40L, not the CD40 receptor. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. Blocking CD40L also increases the polarization of lymphocytes to Tregs, creating a more tolerogenic environment, which provides the potential for better efficacy. CD40L is more selectively expressed than the CD40 receptor, thus having the potential for improved safety, as well as pharmacokinetic, pharmacodynamic, and dosing advantages. By blocking CD40 Ligand on T cells, AT-1501 is inhibiting both events by:

It helps keep the connection at the neuromuscular junction intact because it prevents macrophages from attacking it.

It helps decrease a different population of T cells that cause neuroinflammation and neurotoxicity. So instead of activating the natural immune cells in the spinal cord, it keeps them quiet so that they do not attack the neuron and eliminate it.

Anelixis had successfully raised funds, managing the manufacturing of large-scale quantities of GMP and clinical-grade AT-1501 in partnership with Lonza in the United Kingdom. Additionally, the company originally entered an exclusive licensing agreement with the Amyotrophic Lateral Sclerosis Therapy Development Institute back in 2015 to develop AT-1501 as a potential treatment for Amyotrophic Lateral Sclerosis and other diseases.

In November 2018, Anelixis Therapeutics initiated a Phase I clinical trial of AT-1501, a safety-engineered anti-CD40 ligand monoclonal antibody, following an IND allowance application. The study evaluated the safety and pharmacokinetics of AT-1501 in healthy volunteers and enrolled patients with Amyotrophic Lateral Sclerosis and achieved positive results.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the AT-1501 description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.

Elaborated details on AT-1501 regulatory milestones and other development activities have been provided in this report.

The report also highlights the AT-1501 research and development activities in Amyotrophic Lateral Sclerosis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around AT-1501.

The report contains forecasted sales of AT-1501 for Amyotrophic lateral sclerosis till 2032.

Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.

The report also features the SWOT analysis with analyst views for AT-1501 in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AT-1501 Analytical Perspective by DelveInsight

In-depth AT-1501 Market Assessment

This report provides a detailed market assessment of AT-1501 for Amyotrophic lateral sclerosis in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

AT-1501 Clinical Assessment

The report provides the clinical trials information of AT-1501 for Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AT-1501 dominance.

Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to AT-1501 and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AT-1501 in Amyotrophic Lateral Sclerosis.

Our in-depth analysis of the forecasted sales data of AT-1501 from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AT-1501 in Amyotrophic Lateral Sclerosis.

Key Questions

What is the product type, route of administration and mechanism of action of AT-1501?

What is the clinical trial status of the study related to AT-1501 in Amyotrophic lateral sclerosis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AT-1501 development?

What are the key designations that have been granted to AT-1501 for Amyotrophic Lateral Sclerosis?

What is the forecasted market scenario of AT-1501 for Amyotrophic Lateral Sclerosis?

What are the forecasted sales of AT-1501 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to AT-1501 for Amyotrophic Lateral Sclerosis?

Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?